Actively Recruiting
Cannabis for the Prophylactic Treatment of Migraine
Led by University of Calgary · Updated on 2026-05-01
72
Participants Needed
1
Research Sites
139 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study will evaluate the efficacy and safety of cannabis for the treatment of chronic migraine headaches. Study subjects will be randomized to one of three groups: lower dose CBD, higher dose CBD or placebo.
CONDITIONS
Official Title
Cannabis for the Prophylactic Treatment of Migraine
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Willing and able to give signed informed consent
- Male or female aged 25 years or older
- History of migraine diagnosed by International Classification of Headache Disorders for at least 12 months
- Chronic migraine for at least 3 months before screening
- Stable dose of migraine preventative medications for at least 3 months prior to randomization, with no planned changes during the study
- Females of child-bearing age using reliable contraception
- Failure of at least two prior migraine preventatives due to lack of efficacy or tolerability
- Able to follow study procedures, complete headache diaries and questionnaires
- Completion of at least 90% of headache diary during 1 month baseline period
You will not qualify if you...
- Presence of other active primary headaches (e.g., cluster headache, hemicrania continua)
- Secondary headaches such as those related to intracranial hypertension, hypotension, hydrocephalus, or brain lesions
- Pregnancy, planning pregnancy, or breastfeeding
- Active or significant history of major mental illness including severe depression, anxiety, psychosis, or schizophrenia
- History or current substance use disorder
- Regular cannabis use in past 12 months
- Significant cardiovascular or cerebrovascular disease (e.g., heart attack, stroke, peripheral vascular disease)
- Untreated hypertension over 160/100
- Past history of seizure disorder
- Liver disease or elevated liver enzymes at baseline
- Severe kidney disease or significantly reduced kidney function
- Conditions causing excessive daytime sleepiness such as narcolepsy or sedative overuse
- Any medical condition posing health risk as judged by investigators
- Use of nerve blocks, sphenopalatine ganglion blocks, vagal nerve stimulators, or transcranial magnetic stimulators during baseline or treatment periods
- Use of steroids or dihydroergotamine protocols during baseline or treatment periods
- Overuse of triptans, dihydroergotamine, opioids, or barbiturates (10+ days/month in past 3 months)
- Overuse of simple analgesics or NSAIDs (15+ days/month in past 3 months)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHAMP Research (Calgary Headache Assessment & Management Program)
Calgary, Alberta, Canada, T3M 1M4
Actively Recruiting
Research Team
C
CHAMP Research (Calgary Headache Assessment & Management Prog)
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here